APA (7th ed.) Citation

Eichhorn, F., Klotz, L. V., Bischoff, H., Thomas, M., Lasitschka, F., Winter, H., . . . Eichhorn, M. E. (2019). Neoadjuvant anti-programmed death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): The NEOMUN trial. BMC cancer, 19, . https://doi.org/10.1186/s12885-019-5624-2

Chicago Style (17th ed.) Citation

Eichhorn, Florian, Laura Valentina Klotz, Helge Bischoff, Michael Thomas, Felix Lasitschka, Hauke Winter, Hans Hoffmann, and Martin E. Eichhorn. "Neoadjuvant Anti-programmed Death-1 Immunotherapy by Pembrolizumab in Resectable Nodal Positive Stage II/IIIa Non-small-cell Lung Cancer (NSCLC): The NEOMUN Trial." BMC Cancer 19 (2019). https://doi.org/10.1186/s12885-019-5624-2.

MLA (9th ed.) Citation

Eichhorn, Florian, et al. "Neoadjuvant Anti-programmed Death-1 Immunotherapy by Pembrolizumab in Resectable Nodal Positive Stage II/IIIa Non-small-cell Lung Cancer (NSCLC): The NEOMUN Trial." BMC Cancer, vol. 19, 2019, https://doi.org/10.1186/s12885-019-5624-2.